GlassScriptPhysician profile
Kyndall Scott
NPI 1104530740
$1,703.89
in general payments reported to CMS, 2019-2025
19 companies · $531 in 2025
The $531 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $358 · 2024: $814 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $362.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $221.25 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $171.21 | 2023-2025 | Kerendia |
| Lilly USA, LLC | $129.50 | 2024 | Zepbound, Mounjaro |
| Astellas Pharma US INC | $124.97 | 2023-2025 | Veozah |
| Pfizer INC. | $119.78 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $104.78 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $96.62 | 2024 | |
| Amgen INC. | $88.28 | 2023-2025 | Repatha, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $52.23 | 2024-2025 | Gemtesa |
| Viiv Healthcare Company | $38.63 | 2025 | Dovato |
| Otsuka America Pharmaceutical, INC. | $34.08 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $32.30 | 2023 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.22 | 2023-2024 | Jardiance |
| Abbvie INC. | $27.23 | 2023-2025 | Ubrelvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $19.80 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $17.15 | 2024 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $15.62 | 2024 | Eliquis |
| Idorsia Pharmaceuticals US INC | $15.33 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyndall Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.